Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: A multivariate analysis

Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation

“…This has made it possible to study the effect of well-defined antibodies to transplant outcomes. Several studies have demonstrated the role of preformed donor-specific antibodies for rejection and graft survival [14][15][16]. However, the clinical relevance of antibodies detected with single antigen beads is still controversial and some transplants may be denied based on overcautious risk estimations [17][18][19].…”

De Novo Donor-Specific HLA Antibodies: Biomarkers of Pancreas Transplant Failure

“…This has enabled the further discovery that circulating antibodies directed against donor HLA, or donor‐specific HLA antibodies (DSA), confer the poorest allograft survival both when preformed before transplant and when formed de novo posttransplant. Several studies have investigated the role of DSA in kidney and cardiac transplantation and, to a lesser extent, lung and liver transplantation. However, research into the importance of HLA antibodies in pancreas transplantation has been lacking with only two such series described to date .…”

Platelet donor selection for HLA‐immunised patients; the impact of donor‐specific HLA antibody levels

“…New technologies allow antibodies against specific HLA antigens to be distinguished individually. In solid organ and mismatched haematological stem cell transplant (HSCT) settings, HLA antibodies detected by these methods and directed against donor's antigens (donor‐specific antibodies, DSA) have repeatedly been shown to predict positive cross‐matching, rejection and delayed graft function (Ciurea et al ., ; Lefaucheur et al ., ; Riethmüller et al ., ; Spellman et al ., ; Caro‐Oleas et al ., ; BSHI & BTS, ; Piazza et al ., ; Peräsaari et al ., ; Kongtim et al ., ), but the significant antibody strength cut‐offs are not unequivocal. DSAs are also expected to be the main reason for immunologically mediated platelet refractoriness, but there are few studies on antibody strengths concerning the HLA antibodies of platelet refractory patients (Beligaswatte et al ., ; Jackman et al ., ) and even fewer utilising single antigen assays (Pai et al ., ).…”